Transformative therapies for serious liver disease are at the center of the partnership signed between Takeda and Ambys Medicines, a biotechnology company pioneering the application of cell and gene therapy and gain-of-function drug therapy. The final goal is to identify new treatments able to restore liver function and prevent the progression to liver failure across multiple liver diseases that are currently untreatable or poorly treated. According to Takeda, the company has invested $100 million, including participation in the Series A financing, and received an option to ex-U.S. commercialization rights for the first four products that reach an investigational new drug application. Takeda will also share in 50% of the development costs for any optioned program and will make development and regulatory milestone payments.